Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis

Next Previous
Trial Profile

A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diroximel-fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms EVOLVE-1; EVOLVE-MS-1
  • Sponsors Biogen

    • Most Recent Events

    • 01 Dec 2023 Results of final outcomes , published in the Multiple Sclerosis Journal
    • 13 Oct 2023 Results comparing cohorts from the EVOLVE-MS-1study for DRF and the DECIDE study for IFN beta-1a assessing the efficacy and safety of DRF and IFN beta-1a in adults with relapsing-remitting multiple sclerosis, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
    • 13 Oct 2023 Results of Subgroup analysis, determining whether lymphopenia or magni-tude of ALC decline is correlated with DRF efficacy , presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top